Prostate carcinoma:

470 patients with localized prostate carcinoma are being studied. By ICH we detected 20% positive events in the BM at the time of primary diagnosis. In another series of 132 prostate carcinoma patients we did find an association between tumour size and presence of circulating tumour cells at diagnosis was also as an predictor of early relapse (Øgreid et al), 2001). Together with Professor G. Gaudernack, Department of Immunology, who has developed a vaccine against prostate cancer, we have under development a treatment regimen for prostate cancer patients with circulating tumour cells.